X

Trial Profile

A Phase I Study Of Decitabine (DAC) (IND50733) In Children With Relapsed Or Refractory Acute Leukemia

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary)
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use

Most Recent Events

22 Jan 2013 Actual initiation date changed from Jan 2003 to Dec 2002 as reported by ClinicalTrials.gov.
22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
04 Jun 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com